ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P34-21 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective August 2, 2021
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2251 - 2260 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P3R1-21 Update: eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2021 June Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P36-21 Site of Service for Selected Outpatient Procedures: XI-03 Medical Policy Update
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P35-21 eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P33-21 Change to Medical Review Process for Outpatient Therapies Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP45-21 Medical Drug Update for Botulinum Toxins (Myobloc, Botox, Dysport, Xeomin) - Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 26, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP46-21 Incorrect ID Cards Issued for Minnesota Health Care Programs Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 26, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP43-21 MHCP Pharmacy Benefit Exclusion for Jemperli and Zynlonta™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 26, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP44-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Zeposia® (ozanimod)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 26, 2021